Research Article
Increased Sphingosine Kinase 1 Expression Is Associated with Poor Prognosis in Human Solid Tumors: A Meta-Analysis
Table 1
Main characteristics of the eligible studies.
| | Study | Region | Duration | Cancer type | Sample size | Clinical stage | Follow up (months) | Detection method | Cut-off value | SPHK1-high (%) | Survival analysis | Language | Quality |
| | Hanker 2021 | Canada | 1984-2009 | OC | 1005 | I-IV | NR | IHC | ≥3 | 248 (24.7) | OS (M) | English | 7 | | Yin 2019 | China | 2003-2010 | GC | 120 | I-III | NR | IHC | ≥6 | 44 (36.7) | OS (M) | English | 7 | | Li 2019 | China | NR | PTC | 92 | I-IV | ≥120 | IHC | ≥4 | 35 (38.0) | DFS (M) | English | 8 | | Liu 2019 | China | 2013 | CRC | 114 | I-IV | NR | IHC | ≥3 | 78 (68.4) | OS (U) | English | 6 | | Gachechiladze (S) 2019 | Czech Republic | 1996-2000
2005-2011 | NSCLC | 51 | I-IV | NR | IHC | Median | 34 (66.7) | OS (U), DFS (U) | English | 6 | | Gachechiladze (C) 2019 | Czech Republic | 1996-2000
2005-2011 | NSCLC | 81 | I-IV | NR | IHC | Median | 28 (34.6) | OS (U), DFS (U) | English | 6 | | Bae 2019 | Korea | NR | CRC | 328 | I-III | NR | IHC | ≥4 | 112 (34.1) | OS (M) | English | 7 | | Xu 2018 | China | NR | RCC | 358 | I-IV | 60 | IHC | ﹥6 | 243 (67.9) | OS (U) | English | 6 | | Su 2018 | China | 2013 | CRC | 92 | NR | Median 54 | IHC | ≥10% | 78 (84.8) | OS (U) | English | 6 | | Kato 2018 | Japan | 1996-2014 | OSCC | 69 | I-IV | 60 | IHC | ≥6 | 38 (55.1) | OS (M) | English | 8 | | Zhu 2017 | China | 2006-2013 | BC | 122 | I-III | Median 56.5 | IHC | ≥8 | 64 (52.5) | OS (M), DFS (M) | English | 8 | | Ochnik 2017 | Australian | NR | BC | 236 | I-III | Median 61 | IHC | ≥2 | 123 (52.1) | OS (M), DFS (M) | English | 7 | | Furuya 2017 | USA | 2008 | CRC | 85 | I-IV | Median 57 | IHC | ≥50% | 9 (10.6) | OS (M) | English | 7 | | Fang 2017 | China | 2008-2011 | HCC | 252 | I-IV | NR | IHC | ≥40% | 181 (71.8) | OS (U), DFS (U) | Chinese | 6 | | Cai 2017 | China | 2008-2010 | HCC | 127 | I-IV | 60 | IHC | NR | 93 (73.2) | OS (M) | English | 8 | | Li 2016 | China | NR | PC | 388 | I-IV | 60 | IHC | ≥6 | 230 (59.3) | OS (M) | English | 8 | | Shi 2015 | China | 2000-2004 | HCC | 199 | I-IV | 36 | IHC | ≥20% | 136 (68.3) | OS (U), DFS (U) | English | 6 | | Li 2015 | China | 2007-2009 | NPC | 142 | I-IV | 60 | IHC | ≥6 | 93 (65.5) | OS (M) | English | 7 | | Kin 2015 | Korea | 2002-2009 | CC | 287 | I-II | NR | IHC | ≥4 | 183 (63.8) | OS (M), DFS (M) | English | 7 | | Chen 2015 | Taiwan | 1986-2006 | CCA | 96 | NR | 60 | IHC | ≥50 | 64 (66.7) | OS (M) | English | 8 | | Yang 2014 | China | 2007-2013 | SCLC | 76 | NR | Median 24 | IHC | NR | 53 (69.7) | OS (M) | Chinese | 7 | | Meng 2014 | China | 2005-2008 | BLC | 153 | I-III | 60 | IHC | Median | 82 (53.6) | OS (M) | English | 7 | | Chang 2014 | China | 2009 | NSCLC | 93 | I-III | Until 2018 | IHC | ≥4 | 48 (51.6) | OS (U) | Chinese | 6 | | Ruckhäberle 2013 | Germany | 1999-2001 | BC | 112 | I-III | Median 57.6 | IHC | UQ | 29 (25.9) | OS (U), DFS (U) | English | 6 | | Ohotski 2012 | UK | 1995-1998 | BC | 140 | NR | NR | IHC | NR | 110 (78.6) | DFS (U) | English | 6 | | Zhuge 2011 (I-II) | China | 2001-2005 | GC | 63 | I-II | 60 | IHC | ≥6 | 28 (44.4) | OS (U) | Chinese | 6 | | Zhuge 2011 (III) | China | 2001-2005 | GC | 116 | III | 60 | IHC | ≥6 | 77 (66.4) | OS (U) | Chinese | 6 | | Pan 2011 | China | 2001-2005 | ESCC | 124 | NR | 96 | IHC | ≥2 | 89 (71.8) | OS (U) | English | 6 | | Waston 2010 | UK | 1980-1999 | BC | 267 | NR | Mean 95 | IHC | NR | 95 (35.6) | DFS (U) | English | 6 | | Liu 2010 | China | 1995-2004 | SGC | 159 | I-IV | 60 | IHC | ≥6 | 85 (53.5) | OS (M) | English | 7 | | Li 2009 | China | 1997-2001 | GC | 175 | I-IV | 60 | IHC | ≥6 | 115 (65.7) | OS (M) | English | 8 | | Li 2008 | China | 2000-2005 | AC | 243 | I-IV | NR | IHC | ≥6 | 100 (41.2) | OS (M) | English | 8 |
|
|
OC: ovarian carcinoma; GC: gastric cancer; PTC: papillary thyroid carcinoma; CRC: colorectal cancer; NSCLC: nonsmall cell lung cancer; RCC: renal cell carcinoma; OSCC: oral squamous cell carcinoma; BC: breast cancer; HCC: hepatocellular carcinoma; PC: pancreatic cancer; NPC: nasopharyngeal carcinoma; CC: cervical cancer; CCA: cholangiocarcinoma; SCLC: small cell lung cancer; BLC: bladder cancer; ESCC: esophageal carcinoma; SGC: salivary gland carcinoma; AC: astrocytomas; S: surgery; C: chemotherapy; UQ: upper quartile; IHC: immunohistochemistry; OS overall survival; DFS: disease-free survival; M: multivariate analysis; U: univariate analysis; NR: none reported.
|
